Veracyte enters In Vitro diagnostic agreement with Illumina

Veracyte (VCYT) today announced that it has entered into a multi-year agreement with Illumin (ILMN) to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing instrument. The agreement is part of Veracyte’s expanded, multi-platform IVD approach, which will also include qPCR and is designed to accelerate the company’s ability to make its tests available to more patients globally. The first tests that Veracyte plans to develop for the Illumina NextSeq 550Dx instrument are its Prosigna Breast Cancer Assay and Percepta Nasal Swab test. Prosigna is already commercially available as an IVD test that helps inform treatment decisions for patients with early-stage breast cancer. The noninvasive Percepta Nasal Swab test is intended to help guide diagnosis and treatment decisions for current and former smokers with lung nodules that are potentially cancerous.